Eslovènia - eslovè - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

alkaloid - int d.o.o. - ciklosporin - kapsula, mehka - ciklosporin 50 mg / 1 kapsula - ciklosporin

Eslovènia - eslovè - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

actavis group ptc ehf. - docetaksel - koncentrat in vehikel za raztopino za infundiranje - docetaksel 20 mg / 0,5 ml - docetaksel

Eslovènia - eslovè - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

galex d.d. - topiramat - filmsko obložena tableta - topiramat 200 mg / 1 tableta - topiramat

Eslovènia - eslovè - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

galex d.d. - topiramat - filmsko obložena tableta - topiramat 50 mg / 1 tableta - topiramat

Eslovènia - eslovè - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

galex d.d. - topiramat - filmsko obložena tableta - topiramat 100 mg / 1 tableta - topiramat

Unió Europea - eslovè - EMA (European Medicines Agency)

amgen europe b.v. - blinatumomab - predkroglomerna limfoblastna levkemija limfoma - antineoplastična sredstva - blincyto is indicated as monotherapy for the treatment of adults with cd19 positive relapsed or refractory b precursor acute lymphoblastic leukaemia (all). patients with philadelphia chromosome positive b-precursor all should have failed treatment with at least 2 tyrosine kinase inhibitors (tkis) and have no alternative treatment options. blincyto is indicated as monotherapy for the treatment of adults with philadelphia chromosome negative cd19 positive b-precursor all in first or second complete remission with minimal residual disease (mrd) greater than or equal to 0. blincyto is indicated as monotherapy for the treatment of paediatric patients aged 1 year or older with philadelphia chromosome negative cd19 positive b precursor all which is refractory or in relapse after receiving at least two prior therapies or in relapse after receiving prior allogeneic haematopoietic stem cell transplantation. blincyto is indicated as monotherapy for the treatment of paediatric patients aged 1 year or older with high-risk first relapsed philadelphia chromosome negative cd19 positive b-precursor all as part of the consolidation therapy (see section 4.

Unió Europea - eslovè - EMA (European Medicines Agency)

lipomed gmbh - deferiprone - iron overload; beta-thalassemia - vsi drugi terapevtski izdelki - deferiprone lipomed monotherapy je primerna za zdravljenje železa preobremenitve pri bolnikih z talasemija major, ko se tok chelation therapy je kontraindiciran ali neustrezni. deferiprone lipomed v kombinaciji z drugo chelator je indicirana pri bolnikih z talasemija major, ko monotherapy z vsemi železa chelator je neučinkovita, ali ko je preprečevanje ali zdravljenje življenjsko nevarne posledice železa preobremenitve opravičuje hitro ali intenzivno popravek.

Eslovènia - eslovè - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

topiramat - filmsko obložena tableta - topiramat 200 mg / 1 tableta - topiramat

Eslovènia - eslovè - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

topiramat - filmsko obložena tableta - topiramat 50 mg / 1 tableta - topiramat

Eslovènia - eslovè - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

topiramat - filmsko obložena tableta - topiramat 25 mg / 1 tableta - topiramat